Also known as: Mitochondrial ORF of the 12S rRNA Type-c, MOTS-C peptide
Half-life: Not well characterized in humans (estimated hours based on peptide size)
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome, specifically within the 12S rRNA gene. It was the first identified mitochondrial-derived peptide (MDP) shown to regulate nuclear gene expression by translocating from mitochondria to the cell nucleus in response to metabolic stress. This retrograde signaling mechanism represents a novel form of mito-nuclear communication that challenges the traditional view of mitochondria as passive energy producers.
MOTS-c acts primarily through activation of the AMPK pathway, the master energy sensor of the cell, promoting glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. Its effects closely mimic those of exercise at the molecular level, leading researchers to describe it as an "exercise mimetic." Studies have shown that MOTS-c levels decline with age, and that certain polymorphisms in the MOTS-c gene are associated with exceptional longevity in Japanese centenarian populations.
The metabolic effects of MOTS-c include improved insulin sensitivity, enhanced fat metabolism, protection against diet-induced obesity, and preservation of skeletal muscle function during aging. Animal studies have demonstrated that exogenous MOTS-c administration can reverse age-related metabolic decline and improve physical performance in aged mice. While human clinical data is still emerging, the peptide has generated significant interest in the longevity and metabolic health communities.
MOTS-c was discovered in 2015 by Dr. Changhan David Lee and colleagues at the University of Southern California's Leonard Davis School of Gerontology. It was one of the first mitochondrial-derived peptides (MDPs) identified — peptides encoded within the mitochondrial genome rather than the nuclear genome. The discovery was published in Cell Metabolism and challenged the prevailing view that mitochondria primarily function as passive energy producers. The name stands for "Mitochondrial Open Reading Frame of the 12S rRNA Type-c." Subsequent research revealed its role as an exercise mimetic and its association with exceptional longevity in Japanese centenarians (Fuku et al., 2015). The peptide's ability to translocate from mitochondria to the nucleus to regulate gene expression represented a novel form of retrograde mitochondrial signaling.
MOTS-c tolerability data in humans is limited, as the peptide was only discovered in 2015 and large-scale clinical trials have not been completed. Available evidence from animal studies suggests a favorable safety profile. The peptide is naturally occurring in human cells and its levels decline with age, supporting the concept of exogenous supplementation. Reported side effects from user communities are generally mild and include injection site reactions and temporary changes in blood glucose levels. Given the peptide's effects on glucose metabolism and AMPK activation, individuals with diabetes or those taking glucose-lowering medications should exercise caution.
Dose Range
5-10 mg
Frequency
Three to five times weekly (SubQ)
Duration
4-8 weeks
Dosing information is for educational purposes only. Consult a healthcare professional before using any peptide.
Typical Vial Size
5 mg
Water Type
Bacteriostatic water (BAC water)
Mixing Volume
2 mL
Half-Life
Not well characterized in humans (estimated hours based on peptide size)
Molecular Weight
2174.6 Da
Store reconstituted vial refrigerated at 2-8°C. Use within 21 days. MOTS-c is a relatively stable peptide. Protect from light and excessive heat.
FDA Status
Not FDA approved. Investigational compound with no clinical trials completed for regulatory submission.
Legal Status
Unregulated research chemical in most countries. Not scheduled or controlled.
USA
Not approvedInvestigational compound
EU
Not approvedNot authorized by EMA
UK
Not approvedNot evaluated by MHRA
Australia
Not approvedNot evaluated by TGA
Russia
Not approvedNot authorized
Canada
Not approvedNot authorized by Health Canada
Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C
Nature Communications (2021)
Demonstrated that MOTS-c is an exercise-induced peptide that improves physical performance and muscle homeostasis in aged mice, supporting its role as an exercise mimetic.
View Study →Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P
Cell Metabolism (2015)
Original discovery paper identifying MOTS-c as a mitochondrial-derived peptide that activates AMPK and regulates metabolic homeostasis, preventing diet-induced obesity.
View Study →Fuku N, Paez JG, Sanchis-Gomar F, Santos-Lozano A, Fiuza-Luces C, Garatachea N, Lira VA, Lucia A
Aging Cell (2015)
Identified a specific MOTS-c gene variant associated with exceptional longevity in Japanese centenarians, linking mitochondrial-derived peptides to human aging.
View Study →Track MOTS-c and more with PinnyPeptide.
Sign Up to Track